Nancy Smyth Templeton

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/271034/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reversible Masking Using Low-Molecular-Weight Neutral Lipids to Achieve Optimal-Targeted Delivery. Journal of Drug Delivery, 2012, 2012, 1-9.	2.5	4
2	Oncolytic Viruses for Induction of Anti-Tumor Immunity. Current Pharmaceutical Biotechnology, 2012, 13, 1750-1760.	1.6	56
3	Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans. PLoS ONE, 2012, 7, e34833.	2.5	149
4	PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform. PLoS ONE, 2012, 7, e40452.	2.5	25
5	Hereditary Inclusion Body Myopathy: Single Patient Response to Intravenous Dosing of <i>GNE</i> Gene Lipoplex. Human Gene Therapy, 2011, 22, 1331-1341.	2.7	40
6	<i>In vivo</i> Safety and Antitumor Efficacy of Bifunctional Small Hairpin RNAs Specific for the Human Stathmin 1 Oncoprotein. DNA and Cell Biology, 2011, 30, 715-726.	1.9	34
7	Optimization of Non-Viral Gene Therapeutics Using Bilamellar Invaginated Vesicles. Journal of Genetic Syndromes & Gene Therapy, 2011, 2, .	0.2	6
8	Hereditary inclusion body myopathy: single patient response to <i>GNE</i> gene Lipoplex therapy. Journal of Gene Medicine, 2010, 12, 403-412.	2.8	26
9	A combinatorial approach for targeted delivery using small molecules and reversible masking to bypass nonspecific uptake in vivo. Gene Therapy, 2010, 17, 1085-1097.	4.5	20
10	Liposomes for Gene Transfer in Cancer Therapy. Methods in Molecular Biology, 2010, 651, 271-278.	0.9	3
11	Safety and <i>in vivo</i> Expression of a GNE-Transgene: A Novel Treatment Approach for Hereditary Inclusion Body Myopathy-2. Gene Regulation and Systems Biology, 2009, 3, GRSB.S2210.	2.3	7
12	Nonviral Delivery for Genomic Therapy of Cancer. World Journal of Surgery, 2009, 33, 685-697.	1.6	35
13	PDX-1 Acts as a Potential Molecular Target for Treatment of Human Pancreatic Cancer. Pancreas, 2008, 37, 210-220.	1.1	54
14	Gene and Cell Therapy. , 2008, , .		7
15	Optimization of Nonviral Gene Therapeutics. , 2008, , .		0
16	Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine, 2007, 25, 8687-8701.	3.8	52
17	New Cationic Liposomes for Gene Transfer. , 2006, , 25-28.		0
18	Widespread, Exceptionally High Levels of Histone H3 Lysine 4 Trimethylation Largely Mediate "Privileged―Gene Expression. Gene Expression, 2006, 13, 271-282.	1.2	6

#	Article	IF	CITATIONS
19	Cell-specific Cytotoxicity of Human Pancreatic Adenocarcinoma Cells Using Rat Insulin Promoter Thymidine Kinase-directed Gene Therapy. World Journal of Surgery, 2004, 28, 826-833.	1.6	20
20	Liposomal Nonviral Delivery Vehicles. , 2004, , 721-725.		0
21	Optimization of gene expression in nonactivated circulating lymphocytes. Molecular Therapy, 2003, 8, 629-636.	8.2	12
22	Myths concerning the use of cationic liposomes in vivo. Expert Opinion on Biological Therapy, 2003, 3, 57-69.	3.1	10
23	Alternative Strategies for Targeted Delivery of Nucleic Acid-Liposome Complexes. , 2003, , 1-16.		0
24	Cationic Liposomes as In Vivo Delivery Vehicles. Current Medicinal Chemistry, 2003, 10, 1279-1287.	2.4	61
25	Myths concerning the use of cationic liposomes in vivo. Expert Opinion on Biological Therapy, 2003, 3, 57-69.	3.1	5
26	Optimization of Nonviral Gene Therapeutics. , 2003, , 287-299.		0
27	Enhanced Gene Expression in Breast Cancer Cells in Vitro and Tumors in Vivo. Molecular Therapy, 2002, 6, 783-792.	8.2	43
28	Bilamellar Cationic Liposomes Protect Adenovectors from Preexisting Humoral Immune Responses. Molecular Therapy, 2002, 5, 233-241.	8.2	117
29	Inhibition of Breast Tumor Progression by Systemic Delivery of the Maspin Gene in a Syngeneic Tumor Model. Molecular Therapy, 2002, 5, 755-761.	8.2	73
30	Noninvasive Imaging of Cationic Lipid-Mediated Delivery of Optical and PET Reporter Genes in Living Mice. Molecular Therapy, 2002, 6, 555-562.	8.2	57
31	Liposomal Delivery of Nucleic AcidsIn Vivo. DNA and Cell Biology, 2002, 21, 857-867.	1.9	69
32	Cationic Liposome-Mediated Gene Delivery In vivo. Bioscience Reports, 2002, 22, 283-295.	2.4	77
33	Successful Treatment of Primary and Disseminated Human Lung Cancers by Systemic Delivery of Tumor Suppressor Genes Using an Improved Liposome Vector. Molecular Therapy, 2001, 3, 337-350.	8.2	195
34	Insulinoma-Induced Hypoglycemic Death in Mice is Prevented With Beta Cell-Specific Gene Therapy. Annals of Surgery, 2001, 233, 603-611.	4.2	32
35	Conformational Regulation of the Fibronectin Binding and α3β1 Integrin-mediated Adhesive Activities of Thrombospondin-1. Journal of Biological Chemistry, 2001, 276, 27913-27922.	3.4	29
36	Strategies for Improving the Frequency and Assessment of Homologous Recombination. , 2000, 133, 45-60.		1

#	Article	IF	CITATIONS
37	Thrombospondin-1 promotes alpha3beta1 integrin-mediated adhesion and neurite-like outgrowth and inhibits proliferation of small cell lung carcinoma cells. Cancer Research, 2000, 60, 457-66.	0.9	55
38	Nonviral Vectors for the Treatment of Disease. Nature Biotechnology, 1999, 17, 29-29.	17.5	1
39	New directions in liposome gene delivery. Molecular Biotechnology, 1999, 11, 175-180.	2.4	128
40	Efficient gene targeting in mouse embryonic stem cells. Gene Therapy, 1997, 4, 700-709.	4.5	38
41	Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nature Biotechnology, 1997, 15, 647-652.	17.5	737
42	Characterization of hUCRBP (YY1, NF-E1, Î): A transcription factor that binds the regulatory regions of many viral and cellular genes. Gene, 1994, 150, 259-266.	2.2	63
43	The Polymerase Chain Reaction History Methods, and Applications. Diagnostic Molecular Pathology, 1992, 1, 58-72.	2.1	80
44	Cloning and characterization of a novel human cDNA that has DNA similarity to the conserved region of the collagenase gene family. Genomics, 1992, 12, 175-176.	2.9	15